Maze Therapeutics, Inc. Common Stock MAZE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|
| Liquidity | |||
| Current ratio | 17.9×+2.4× | 15.5×-2.2× | |
| Quick ratio | 17.9×+2.4× | 15.5×-2.2× | |
| Cash ratio | 9.4×+1.0× | 8.4×-5.9× | |
| Leverage | |||
| Debt-to-equity | 0.2×+0.1× | 0.1×— | |
| Debt-to-assets | 0.1×+0.1× | 0.1×0.0× | |
| Per Share | |||
| Book value per share | $6.34-23.2% | $8.26-0.3% | |
| Valuation | |||
| Market capitalization | $1.5B+205% | —— | |
| Enterprise value | $1.36B— | —— | |
| Price / book | 4.4×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Maze Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Maze Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
